British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

R.H. McAllister-William; D.S. Baldwin; R. Cantwell; Abigail Easter; E. Gilvarry; V Glover; L. Green; A. Gregoire; LM Howard; I. Jones; H Khalifeh; A.  Lingford-Hughes; E. McDonald; Nadia Micali; Carmine Pariante; L. Peters; A. Robert; N. Smit; Dl Taylor; A. Wieck; L.M. Yates; A.H. Young

doi:10.1177/0269881117699361

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

R.H. McAllister-William, D.S. Baldwin, R. Cantwell, Abigail Easter, E. Gilvarry, V Glover, L. Green, A. Gregoire, LM Howard, I. Jones, H Khalifeh, A. Lingford-Hughes, E. McDonald, Nadia Micali, Carmine Pariante, L. Peters, A. Robert, N. Smit, Dl Taylor, A. WieckL.M. Yates, A.H. Young

Research output: Contribution to journal › Article › peer-review

159 Citations (Scopus)

429 Downloads (Pure)

Abstract

Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

Original language	English
Pages (from-to)	519-552
Journal	Journal of Psychopharmacology
Volume	31
Issue number	5
Early online date	25 Apr 2017
DOIs	https://doi.org/10.1177/0269881117699361
Publication status	Published - 2017

Keywords

Antidepressants, antipsychotics, anxiolytics, birth defects, breastfeeding, child development, conception, fertility, hypnotics, mood stabilisers, neonatal problems, postpartum, pregnancy, pregnancy outcome, psychiatric illness, psychotropics, teratogenicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/0269881117699361

British Association for Psychopharmacology_MCALLISTER-WILLIAM_Publishedonline25April2017_GREEN AAMAccepted author manuscript, 1.17 MB

Cite this

McAllister-William, R. H., Baldwin, D. S., Cantwell, R., Easter, A., Gilvarry, E., Glover, V., Green, L., Gregoire, A., Howard, LM., Jones, I., Khalifeh, H., Lingford-Hughes, A., McDonald, E., Micali, N., Pariante, C., Peters, L., Robert, A., Smit, N., Taylor, D., ... Young, A. H. (2017). British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. Journal of Psychopharmacology, 31(5), 519-552. https://doi.org/10.1177/0269881117699361

@article{1025ceb3ca504b3a8d91ba8a3dfa93b4,

title = "British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017",

abstract = "Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.",

keywords = "Antidepressants, antipsychotics, anxiolytics, birth defects, breastfeeding, child development, conception, fertility, hypnotics, mood stabilisers, neonatal problems, postpartum, pregnancy, pregnancy outcome, psychiatric illness, psychotropics, teratogenicity",

author = "R.H. McAllister-William and D.S. Baldwin and R. Cantwell and Abigail Easter and E. Gilvarry and V Glover and L. Green and A. Gregoire and LM Howard and I. Jones and H Khalifeh and A. Lingford-Hughes and E. McDonald and Nadia Micali and Carmine Pariante and L. Peters and A. Robert and N. Smit and Dl Taylor and A. Wieck and L.M. Yates and A.H. Young",

year = "2017",

doi = "10.1177/0269881117699361",

language = "English",

volume = "31",

pages = "519--552",

journal = "Journal of Psychopharmacology",

issn = "0269-8811",

publisher = "SAGE Publications Ltd STM",

number = "5",

}

McAllister-William, RH, Baldwin, DS, Cantwell, R, Easter, A, Gilvarry, E, Glover, V, Green, L, Gregoire, A, Howard, LM, Jones, I, Khalifeh, H, Lingford-Hughes, A, McDonald, E, Micali, N, Pariante, C, Peters, L, Robert, A, Smit, N, Taylor, D, Wieck, A, Yates, LM & Young, AH 2017, 'British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017', Journal of Psychopharmacology, vol. 31, no. 5, pp. 519-552. https://doi.org/10.1177/0269881117699361

TY - JOUR

T1 - British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

AU - McAllister-William, R.H.

AU - Baldwin, D.S.

AU - Cantwell, R.

AU - Easter, Abigail

AU - Gilvarry, E.

AU - Glover, V

AU - Green, L.

AU - Gregoire, A.

AU - Howard, LM

AU - Jones, I.

AU - Khalifeh, H

AU - Lingford-Hughes, A.

AU - McDonald, E.

AU - Micali, Nadia

AU - Pariante, Carmine

AU - Peters, L.

AU - Robert, A.

AU - Smit, N.

AU - Taylor, Dl

AU - Wieck, A.

AU - Yates, L.M.

AU - Young, A.H.

PY - 2017

Y1 - 2017

N2 - Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

AB - Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

KW - Antidepressants, antipsychotics, anxiolytics, birth defects, breastfeeding, child development, conception, fertility, hypnotics, mood stabilisers, neonatal problems, postpartum, pregnancy, pregnancy outcome, psychiatric illness, psychotropics, teratogenic

U2 - 10.1177/0269881117699361

DO - 10.1177/0269881117699361

M3 - Article

SN - 0269-8811

VL - 31

SP - 519

EP - 552

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

IS - 5

ER -

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this